CG Oncology, Inc. Common stock (CGON) Earnings History
Annual and quarterly earnings data from 2021 to 2025
Loading earnings history...
CGON EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CGON Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | -15.0% | -4722.1% | -3985.0% |
| 2024 | 100.0% | -10067.3% | -7729.5% |
| 2023 | 100.0% | -27180.9% | -23827.0% |
| 2022 | 92.1% | -18453.4% | -18556.5% |
| 2021 | 99.9% | -121.7% | -124.0% |
Download Data
Export CGON earnings history in CSV or JSON format
Free sign-in required to download data
CG Oncology, Inc. Common stock (CGON) Earnings Overview
As of May 8, 2026, CG Oncology, Inc. Common stock (CGON) reported trailing twelve-month net income of -$161M, reflecting -47.5% year-over-year growth. The company earned $-2.08 per diluted share over the past four quarters, with a net profit margin of -3985.0%.
Looking at the long-term picture, CGON's historical earnings data spans multiple years. The company achieved its highest annual net income of -$13M in fiscal 2021.
CG Oncology, Inc. Common stock is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including GRVY ($80.77B net income, 12.0% margin), IMVT (-$464M net income), TGTX ($462M net income, 72.6% margin), CGON has room to improve margins relative to the peer group. Compare CGON vs GRVY →
CGON Earnings vs Peers
Earnings metrics vs comparable public companies
CGON Historical Earnings Data (2021–2025)
5 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$161M | -82.9% | -$191M | $-2.08 | -3985.0% | -4722.1% |
| 2024 | -$88M | -81.1% | -$115M | $-1.41 | -7729.5% | -10067.3% |
| 2023 | -$49M | -37.1% | -$55M | $-1.02 | -23827.0% | -27180.9% |
| 2022 | -$35M | -176.1% | -$35M | $-0.66 | -18556.5% | -18453.4% |
| 2021 | -$13M | - | -$13M | $-0.28 | -124.0% | -121.7% |
See CGON's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CGON Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CGON vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCGON — Frequently Asked Questions
Quick answers to the most common questions about buying CGON stock.
Is CGON growing earnings?
CGON EPS fell to $-2.08, with earnings declining -47.5%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-161M.
What are CGON's profit margins?
CG Oncology, Inc. Common stock net margin is -3985.0%, with operating margin at -4722.1%. Below-average margins reflect competitive or cost pressures.
How consistent are CGON's earnings?
CGON earnings data spans 2021-2025. The declining earnings trend is -47.5% YoY. Historical data enables comparison across business cycles.